Skip to main content

Research Repository

Advanced Search

The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts

Rida, Padmashree C. G.; Alsaleem, Mansour; Toss, Michael S.; Joseph, Chitra; Aleskandarany, Mohammed; Kurozumi, Sasagu; Alshankyty, Ibrahim; Ogden, Angela; Rida, Padmashree C.G.; Ellis, Ian O.; Aneja, Ritu; Green, Andrew R.; Mongan, Nigel P.; Rakha, Emad A.

Authors

Padmashree C. G. Rida

Mansour Alsaleem

Michael S. Toss

Mohammed Aleskandarany

Sasagu Kurozumi

Ibrahim Alshankyty

Angela Ogden

Padmashree C.G. Rida

Ritu Aneja

NIGEL MONGAN nigel.mongan@nottingham.ac.uk
Professor of Oncology

EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology



Abstract

© 2019, United States & Canadian Academy of Pathology. E-cadherin is a tumor suppressor gene in invasive lobular breast cancer. However, a proportion of high-grade ductal carcinoma shows reduced/loss of E-cadherin. In this study, we assessed the underlying mechanisms and molecular implications of E-cadherin loss in invasive ductal carcinoma. This study used large, well-characterized cohorts of early-stage breast cancer-evaluated E-cadherin expression via various platforms including immunohistochemistry, microarray analysis using Illumina HT-12 v3, copy number analysis using Affymetrix SNP 6.0 arrays, and next-generation sequencing for differential gene expression. Our results showed 27% of high-grade invasive ductal carcinoma showed reduced/loss of E-cadherin membranous expression. CDH1 copy number loss was in 21% of invasive ductal carcinoma, which also showed low CDH1 mRNA expression (p = 0.003). CDH1 copy number was associated with copy number loss of TP53, ATM, BRCA1, and BRCA2 (p < 0.001). Seventy-nine percent of invasive ductal carcinoma with reduced CDH1 mRNA expression showed elevated expression of E-cadherin transcription suppressors TWIST2, ZEB2, NFKB1, LLGL2, CTNNB1 (p < 0.01). Reduced/loss E-cadherin expression was associated with differential expression of 2143 genes including those regulating Wnt (FZD2, GNG5, HLTF, WNT2, and CER1) and PIK3-AKT (FGFR2, GNF5, GNGT1, IFNA17, and IGF1) signaling pathways. Interestingly, key genes differentially expressed between invasive lobular carcinoma and invasive ductal tumors did not show association with E-cadherin loss in invasive ductal carcinoma. We conclude that E-cadherin loss in invasive ductal carcinoma is likely a consequence of genomic instability occurring during carcinogenesis. Potential novel regulators controlling E-cadherin expression in invasive ductal carcinoma warrant further investigation.

Citation

Rida, P. C. G., Alsaleem, M., Toss, M. S., Joseph, C., Aleskandarany, M., Kurozumi, S., …Rakha, E. A. (2019). The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. Modern Pathology, 32(7), 967-976. https://doi.org/10.1038/s41379-019-0209-9

Journal Article Type Article
Acceptance Date Dec 28, 2018
Online Publication Date Feb 13, 2019
Publication Date Jul 1, 2019
Deposit Date Jan 14, 2019
Publicly Available Date Mar 29, 2024
Journal Modern Pathology
Electronic ISSN 1530-0285
Publisher Nature Publishing Group
Peer Reviewed Peer Reviewed
Volume 32
Issue 7
Pages 967-976
DOI https://doi.org/10.1038/s41379-019-0209-9
Keywords E-cadherin; mechanisms; invasive ductal carcinoma; copy number; Next generation sequence
Public URL https://nottingham-repository.worktribe.com/output/1450005
Publisher URL https://www.nature.com/articles/s41379-019-0209-9